Important notice

Meds75+ – information regarding the use for persons aged 75+

Substances A-Z
  • Eb

  • Ebastinum
    Class A
    Suitable for older persons. May cause fatigue.
  • Ec

  • Econazoli nitras
    Class C
    Topical treatment: Suitable for older persons, with specific cautions. In topical use, absorption takes place through broken skin. Take severe adverse effects into account, especially with warfarin.
  • Em

  • Empagliflozinum
    Class C
    Suitable for older persons, with specific cautions. Reduce the dose even in moderate renal insufficiency. Do not use in severe renal insufficiency. Consider the risk of dehydration and urinary tract infection.
  • En

  • Enalaprili maleas
    Class C
    Suitable for older persons, with specific cautions. Reduce the dose in even moderate renal insufficiency. Monitor renal function during the pharmacotherapy. Avoid concurrent use of anti-inflammatory analgesics.
  • Enoxaparinum natricum
    Class C
    Suitable for older persons, with specific cautions. Reduce the dose in even moderate renal insufficiency. A significant adverse effect is increased risk of bleeding.
  • Entacaponum
    Class A
    Suitable for older persons. Start therapy under specialist supervision. Contraindicated in hepatic insufficiency. Adverse effects include nausea, gastrointestinal symptoms and dyskinesia.
  • Ep

  • Ephedrini hydrochloridum
    Class D
    Avoid use in older persons. Do not use on patients with an ischaemic heart disease. Avoid use in severe renal or hepatic insufficiency. Significant adverse effects include insomnia, tremor, palpitations, elevated blood pressure and urinary retention. Take interactions into account.
  • Es

  • Estradioli valeras
    Class D
    Systemic use: Avoid use in older persons. Contraindication is oestrogen-dependent cancer. In systemic use, take adverse effects into account, such as risk of cardiovascular diseases and venous thromboembolisms. Take interactions into account.
    Class D
    Intravaginal therapy: Suitable for older persons. Systemic use: Avoid use in older persons. Contraindication is oestrogen-dependent cancer. In systemic use, take adverse effects into account, such as risk of cardiovascular diseases and venous thromboembolisms. Take interactions into account.
  • Estradiolum hemihydricum
    Class D
    Intravaginal therapy: Suitable for older persons. Systemic use: Avoid use in older persons. Contraindication is oestrogen-dependent cancer. In systemic use, take adverse effects into account, such as risk of cardiovascular diseases and venous thromboembolisms. Take interactions into account.
    Class D
    Systemic use: Avoid use in older persons. Contraindication is oestrogen-dependent cancer. In systemic use, take adverse effects into account, such as risk of cardiovascular diseases and venous thromboembolisms. Take interactions into account.
  • Estriolum
    Class D
    Intravaginal therapy: Suitable for older persons. Systemic use: Avoid use in older persons. Contraindication is oestrogen-dependent cancer. In systemic use, take adverse effects into account, such as risk of cardiovascular diseases and venous thromboembolisms. Take interactions into account.
  • Et

  • Etoricoxibum
    Class C
    Suitable for older persons, with specific cautions. For short-term use only. May decrease renal function. Avoid use in severe renal insufficiency. May increase blood pressure, worsen cardiac insuffiency and cause cardiovascular events. Increases risk of gastrointestinal bleeding less than nonselective anti-inflammatory analgesics.Take interactions into account, especially with anticoagulants. Remember that anti-inflammatory analgesics are commonly used in self-care.
  • Ex

  • Exenatidum
    Class C
    Suitable for older persons, with specific cautions. Limited practical experience of the long-acting preparation. Reduce the dose in moderate renal insufficiency. Do not use in severe renal insufficiency. Weight loss may occur.
  • Ez

  • Ezetimibum
    Class B
    There is a lack of research evidence, clinical experience or efficacy among older persons. For now, the research evidence of monotherapy is scarce.

Icon explanation

Class A A (green): Suitable for the older persons. The medicinal substance can be used as in younger patients. Changes due to aging do not affect the dose or frequency of administration, and the adverse reaction profile is not different from that of younger patients.

Class B B (grey): There is little research evidence, practical experience or efficacy in older persons.

Class C C (yellow): Suitable for older persons, with specific cautions. The medicinal substance can be used by older persons, but the dose might either have to be reduced, or the frequency of administration decreased due to mild or moderate renal insufficiency or a significant risk of interactions or adverse reactions.

Class D D (red): Avoid use in older persons. Use is possible only in exceptional cases or on a one-off basis. Changes due to aging predispose older persons to adverse or dangerous reactions to the drug. The risk of adverse reactions typically exceeds the benefits.

Meds75+ data source is Finnish Medicines Agency Fimea (licensed under CC BY 4.0).
Data updated on Mar 30, 2021.